

11th INTERNATIONAL CONFERENCE



ADVANCES IN PNEUMOLOGY

November 6–7, 2015
Cologne | Germany

www.pneumology.pl



We thank the following companies for their special support:

Gold Sponsor

Heinen + Löwenstein GmbH & Co. KG (Cologne/DE)



Silver Sponsor

TEVA GmbH (Berlin/DE)



Bronze Sponsor

AstraZeneca GmbH (Wedel/DE)



GlaxoSmithKline (Munich/DE)



Grifols Deutschland GmbH (Frankfurt a. M./DE)



Mundipharma Deutschland GmbH & Co. KG (Limburg/DE)



Novartis Pharma GmbH (Nuremberg/DE)



Sponsor

ResMed GmbH & Co. KG Marketing (Martinsried/DE)



Exhibitor

Chiesi GmbH (Hamburg/DE)

PneumRx GmbH, a BTG International group company (Duesseldorf/DE)

State at printing

Conference Organizers	4
Welcome Note Conference Chair	5
General Information	6
Social Program.....	8
Information for Presenters	9
Program Overview.....	10
Scientific Program	
Friday, November 6, 2015	12
Saturday, November 7, 2015.....	21
Author Index	26

Conference Host and Chairman

Dr. med. Justus de Zeeuw

Cologne, Germany

Internal Medicine, Respiratory Medicine, Sleep Medicine

Organizers and Scientific Committee

Prof. Dr. med. Mieczyslaw Pokorski

Biophilia

Warsaw, Poland

Prof. Dr. med. Kurt Rasche

HELIOS Klinikum Wuppertal

Bergisches Lungenzentrum

Klinikum der Universität Witten/Herdecke

Wuppertal, Germany

Prof. Dr. med. Wolfram Windisch

Cologne, Germany

Professional Conference Organization

Conventus Congressmanagement & Marketing GmbH

Juliane Börner

Carl-Pulfrich-Straße 1 • 07745 Jena, Germany

Phone +49 3641 31 16-347

juliane.boerner@conventus.de, www.conventus.de

Design/Layout

Layout

www.krea.tif-design.de

Print

www.kerndruck.de

Circulation

200

Editorial Deadline

October 27, 2015



© Uli Preuss

Dear Colleagues,

I am honoured to be hosting the 2015 International Conference “Advances in Pneumology” in my home city of Cologne.

Cologne is world famous for many things: its roman origin, still present in historic sites as well as it's impressive roman and gothic churches, international cultural events, cologne carnival and last but not least the locally brewed beer, called Kölsch.

This year's scientific programme covers a broad spectrum of respiratory physiology and medicine. Excellent speakers with international reputation will give insights in current developments and future tasks concerning diagnostic and therapy of respiratory diseases.

The success of our meeting depends on our dedicated and loyal participants, who join us for our Congress each year. I'd like to extend a warm welcome to all the new attendees who join us this year.

Welcome to Cologne,

Yours

A handwritten signature in black ink, appearing to read 'Justus de Zeeuw'. The signature is fluid and cursive.

Justus de Zeeuw, MD PhD

Venue

KOMED im MediaPark GmbH
 Im MediaPark 6
 50670 Köln, Germany

Date

November 6–7, 2015

Conference Language

The lectures will be held in English.

Registration

It would be desirable to register online in the forerun of the conference. The registration desk will be open during the following times:

Opening times

Friday	07:30–18:00
Saturday	07:30–13:00

Please be prepared to present a proof of your advanced payment and, if applicable, a proof of your student status. Here you can also pick up your conference materials. On-site registration is also possible. Please note, that only cash payment will be accepted. Registration fees are as follows:

Medical student	50 EUR
Regular	150 EUR
Accompanying person	60 EUR
Late payment at the conference	180 EUR

Welcome Reception, November 5	included
Social Evening, November 6	included

Name Badge

Participants, accompanying persons and exhibitors are kindly requested to wear their name badge during all conference events. Admittance to the scientific sessions, exhibition, and social events will be refused if the required badge cannot be presented. Lost badges will be replaced at the registration desk upon presentation of a proof of registration and an identity card.

Catering

Free lunches will be offered to all delegates during lunchtime at designated desks. Tea and coffee will be available free of charge in the morning and in the afternoon coffee breaks.

Industrial Exhibition

AIP 2015 will host a trade exhibition. For a listing of the exhibitors please refer to the corresponding section in this program (page 10).

Certificate of Participation

At the end of the conference you can pick up your certificate of participation at the registration desk.

Technical Information

Please prepare your presentation as PDF, MS Office Power-Point2010, 2007 for Windows or key for Macintosh DVD in 4:3 aspect ratio.

A presentation notebook with a PDF reader and MS Office Power-Point2010, 2007 will be provided.

A notebook, presenter and laser pointer are available at the speaker podium in the lecture halls.

Please note: Certain encodings for video and audio files could lead to problems.

Please prepare your presentation for the allotted amount of time.

We would like to thank the "Rhein-Ruhr-Stiftung" for their financial support (3.000 EUR) of the abstract publication.

Welcome Reception

Date	Thursday, November 5, 2015
Start	19:00
Price per person	included
Address	Friesenstraße 64-66 50670 Cologne, Germany

On November 5 at 19:00 there will be a Welcome Reception at the “Päffgen Kölsch”. Enjoy the first meeting with your colleagues and other delegates in a relaxed atmosphere with light refreshments.

The Welcome Reception is included in the registration fee, but you are kindly asked to book separately through the registration website.



© www.paeffgen-koelsch.de

Social Evening

Date	Friday, November 6, 2015
Start	20:00
Price per person	included
Address	Frankenwerft 31-33 50667 Cologne, Germany

The Social Evening will take place at the “Ex-Vertretung” on November 6 at 20:00. Do not miss the extraordinary voice of musical star Anja Odenthal!

The Social Evening is included in the registration fee, but you are kindly asked to book separately through the registration website.



© www.ex-vertretung.de

Die schlaflose Gesellschaft



23. JAHRESTAGUNG der Deutschen Gesellschaft für Schlafforschung und Schlafmedizin e. V.

3.–5. Dezember
2015
Rheingoldhalle Mainz

© Kurt Groß, Bildarchiv Südliche Weinstrasse e. V.



Programminhalte

- Fort- und Weiterbildungskurse
- Forum Junge Wissenschaftler
- Freie Vorträge
- Industriesessions
- Kolleg Schlafmedizin
- Patientenforum
- Posterführungen/-vorträge
- Kurzvorträge
- Sitzungen der Arbeitsgruppen der DGSM
- Wissenschaftliche Symposien
- Zahnärztliche Schlafmedizin

Zertifiziert mit 18 Punkten der Kategorie B
durch die Landesärztekammer Rheinland-Pfalz



Informationen und Registrierung: www.dgsm-kongress.de

PROGRAM OVERVIEW

Friday, November 6, 2015		
Room 1	Room 2	Room 4-5
	09:00–09:15	
	Opening	
09:15–10:30	09:15–10:30	09:15–10:30
Smoking and smoking cessation p. 12	Pediatric respirology and hereditary disorders/Respiratory infections I p. 12	Asthma, respiratory allergy and cough I p. 13
Coffee Break		
11:00–12:45	11:00–12:45	11:00–12:45
Pulmonary hypertension/ Psychosomatic aspects p. 13	Respiratory infections II p. 14	Asthma, respiratory allergy and cough II p. 14
Lunch		
13:30–15:00	13:30–15:00	13:30–15:00
Psychosomatic aspects p. 15	Respiratory infections III p. 16	Asthma, respiratory allergy and cough III p. 16
Coffee Break		
15:30–17:15	15:30–17:15	15:30–17:15
Sleep-related breathing disorders I p. 17	Respiratory infections IV p. 17	Asthma, respiratory allergy and cough IV/ Oncology of the chest I p. 18
17:30–19:00	17:30–19:00	17:30–19:00
Oncology/Medical rehabilitation/ Sleep-related... II p. 19	Cardiorespiratory functions p. 19	Oncology of the chest I p. 20
20:00–00:00		
Dinner p. 8		

Saturday, November 7, 2015		
Room 1	Room 2	Room 4-5
09:15–10:30	09:15–10:30	09:15–10:30
Interstitial lung diseases p. 21	Lung function p. 21	Oncology of the chest II p. 22
Coffee Break		
11:00–12:45	11:00–12:45	11:00–12:45
Bronchitis and COPD/Non-invasive ventilation p. 22	Lung function/ Pathophysiology of hypoxia p. 23	Inflammation and clinical immunology p. 24
Farewell Lunch		

*The clinical, public health and
political aspects of tobacco smoking*

The Tobacco Epidemic

2nd, revised and extended edition

Editors

R. Loddenkemper, Berlin
M. Kreuter, Heidelberg


Tobacco use continues to be the leading preventable cause of death worldwide. This new book provides a comprehensive update of the clinical, public health and political aspects of tobacco smoking. The editors have invited the international who's who in the field to create a unique book that is both highly scientific and easy to read.

This book is a must-read for anyone who treats patients with smoking-related diseases and for those engaged in tobacco control, and will also be of interest to journalists and legislators.

See the full table of contents, read free sample chapters and place your order on the book website:

www.karger.com/prrer

KARGER 125 YEARS



The Tobacco Epidemic

2nd, revised and extended edition
(Progress in Respiratory Research, Vol. 42)

X + 276 p., 85 fig., 31 in color, 29 tab., 2015
ISBN 978-3-318-02656-6

List price: EUR 179.00 / CHF 192.00

Special offer: EUR 116.00 / CHF 125.00

Please quote the promotional code
K115459 in your order.

Prices subject to change, VAT not included.
EUR price for eurozone countries only

- 09:00–09:15 **Opening**
Room 2 J. de Zeeuw (Cologne/DE), M. Pokorski (Opole/PL), K. Rasche (Wuppertal/DE)
- 09:15–10:30 **Smoking and smoking cessation**
Room 1
Chairs J. de Zeeuw (Cologne/DE), E. Dzięciołowska-Baran (Szczecin/PL)
- 09:15 Cigarette smoking and respiratory system diseases in college students
ID 25 A. Saracen (Radom/PL)
- 09:30 Adiponectin and mortality in smokers and non-smokers of Ludwigshafen Risk and Cardiovascular Health (LURIC) Study
ID 70 R. Siekmeier (Bonn/DE)
- 09:45 Relationships between respiratory function tests and life habits of the university students in Poland
ID 83 E. Dzięciołowska-Baran (Szczecin/PL)
- 10:00 Intermittent Hypoxia and cigarette smoke – the effect on Nrf2 nuclear localization in HaCaT keratinocytes
ID 97 A. Z. Reznick (Haifa/IL)
- 10:15 The renin-angiotensin-aldosterone system in smokers and non-smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study
ID 107 R. Siekmeier (Bonn/DE)
- 09:15–10:30 **Pediatric respirology and hereditary disorders/Respiratory infections I**
Room 2
Chairs A. Nitsch-Osuch, E. Kuchar (Warsaw/PL)
- 09:15 How much do your asthma patients really cough? – evaluation of the LeoSound-monitor for standardized detection of nocturnal wheezing and cough in childhood
S. Kerzel (Regensburg/DE)
- 09:45 Frequency of rare alpha-1-antitrypsin variants in a group of Polish patients with chronic respiratory disorders
ID 17 K. Duk (Warsaw/PL)
- 10:00 The incidence and clinical course of respiratory viral co-infections in children aged 0–59 months
ID 6 A. Nitsch-Osuch (Warsaw/PL)

09:15
ID 15

High antibiotic prescription rates among children with Influenza
A. Nitsch-Osuch (Warsaw/PL)

09:15–10:30
Room 4-5
Chairs

Asthma, respiratory allergy and cough I

A. Badyda (Warsaw/PL), K. Rasche (Wuppertal/DE)

09:15
ID 2, 3

Chronic cough as a gender issue
J. Plevkova (Martin/SK)

09:45
ID 10

Cough in Guinea pigs sensitized by house dust mite particles as part of development and validation of new model of airway hypersensitivity
T. Buday (Martin/SK)

10:00
ID 22

Incidence of selected pulmonary diseases depending on the exposure to ambient PM10
A. Badyda (Warsaw/PL)

10:15
ID 31

The impact of gender and BMI on the clinical course of COPD and bronchial asthma
K. Wytrychowski (Wrocław/PL)

11:00–12:45
Room 1
Chairs

Pulmonary hypertension/Psychosomatic aspects

M. Pokorski (Opole/PL), C. Witte (Bonn/DE)

11:00

Sensing arterial oxygen content – appraisal and reappraisal
M. Pokorski (Opole/PL)

11:30
ID 40

The effect of pulmonary hypertension on arrhythmias, heart rate variability and conduction system of the heart
C. Witte (Bonn/DE)

11:45
ID 100

Endothelial pathways mediating the prevention of pulmonary hypertension by atrial natriuretic peptide
F. Werner (Wuerzburg/DE)

12:00
ID 7

Quality of visits for patients with chronic respiratory diseases – data for accreditation plan within primary health care
D. Kurpas (Wrocław, Opole/PL)

- 12:15 ID 11 The environmental domain of quality of life in patients with chronic respiratory diseases
D. Kurpas (Wrocław, Opole/PL)
- 12:30 ID 27 Olfactory function in hypoxia
R. Ruffini (Chieti/IT)
- 11:00–12:45 **Respiratory infections II**
Room 2
Chairs E. Kuchar, E. Hallmann-Szelinska (Warsaw/PL)
- 11:00 ID 88, 89 Pertussis – the history of the disease and present prevention failure
E. Kuchar (Warsaw/PL)
- 11:30 ID 19 Viral infections in the age group of 0–14 years old during epidemic season 2014/2015 in Poland
E. Hallmann-Szelińska (Warsaw/PL)
- 11:45 ID 20 Virological characterization of 2014–2015 influenza season based on molecular analysis of biological material from I-MOVE study
E. Hallmann-Szelińska (Warsaw/PL)
- 12:00 ID 23 Clostridium difficile infection due to pneumonia treatment – mortality risk model
M. Chmielewska (Warsaw/PL)
- 12:15 ID 24 Antibiotic treatment in community and hospital acquired pneumonia complicated by Clostridium difficile infection
K. Zycinska (Warsaw/PL)
- 12:30 ID 38 Active case finding among homeless people as a means of reducing the incidence of pulmonary tuberculosis in general population
J. Romaszko (Olsztyn/PL)
- 11:00–12:45 **Asthma, respiratory allergy and cough II**
Room 4-5
Chairs M. Leidag (Wuppertal/DE), J. Mokřý (Martin/SK)
- 11:00 ID 32 Effects of selective inhibition of PDE4 by YM976 on airway reactivity and cough in ovalbumin-sensitized guinea pigs
J. Mokřý (Martin/SK)

- 11:15
ID 33 Computer modeling of neuronal excitation in the Bötzing complex area
M. Veternik (Martin/SK)
- 11:30
ID 36 Influence of olprinone, PDE3 inhibitor, on airway reactivity in ovalbumin-sensitized guinea pigs
M. Kertys (Martin/SK)
- 11:45
ID 37 Volume related feedback can control cough motor pattern – experiments on cats
Z. Kotmanova (Martin/SK)
- 12:00
ID 45 The pattern of tracheobronchial coughing is altered by reduced vagal afferent drive
M. Simera (Martin/SK)
- 12:15
ID 61 The bronchodilatory, antitussive and anti-inflammatory effect of morin in experimental conditions of allergic asthma
I. Kazimierová (Martin/SK)
- 12:30
ID 62 Combination therapy with budesonide and salmeterol under the condition of experimentally induced allergic inflammation
L. Pappová (Martin/SK)
- 13:30–15:00
Room 1
Chairs **Psychosomatic aspects**
A. Z. Reznick (Haifa/IL), M. Pokorski (Warsaw/PL)
- 13:30 The stress reaction – a historical perspective
A. Z. Reznick (Haifa/IL)
- 14:15
ID 34 Cardiac vagal control and depressive symptoms in response to negative emotional stress
M. Mestanik (Martin/SK)
- 14:30
ID 35 Electrodermal activity in adolescent depression
M. Mestanik (Martin/SK)
- 14:45
ID 114 The physical activity level and the quality of life in children with bronchial asthma
A. Pirogowicz-Hirnle (Wrocław/PL)

13:30–15:00 Respiratory infections III

Room 2

Chairs R. Siekmeier (Bonn/DE), K. Bednarska (Warsaw/PL)

13:30 Participation of pathogens caused upper respiratory tract
ID 44 infections in outpatients

A. Jama-Kmiecik (Wrocław/PL)

13:45 Antigenic drift of A/H3N2/Virus and circulation of
ID 47 influenza – like viruses during the 2014/2015 influenza season in Poland
K. Bednarska (Warsaw/PL)14:00 Diagnosis of invasive pulmonary aspergillosis
ID 48 D. Przybyłowska (Warsaw/PL)14:15 Molecular characteristic of influenza virus type B lineages
ID 49 circulating in Poland
K. Bednarska (Warsaw/PL)14:30 Severe course of Whooping Cough in adults – a series of cases
ID 56 M. Cieplak (Warsaw/PL)14:45 Vitamin D deficiency as a risk factor for tuberculosis
ID 76 R. Siekmeier (Bonn/DE)**13:30–15:00 Asthma, respiratory allergy and cough III**

Room 4-5

Chairs M. Kostrzon (Wieliczka/PL), M. Kocmalova (Martin/SK)

13:30 The relationship of theophylline plasma levels to its bronchodilator and
ID 63 anti-inflammatory effects in a model of ovalbumin-induced allergic
inflammation

A. Urbanová (Martin/SK)

13:45 Chemical analysis of air in the complex of underground chambers of the
ID 64 “Wieliczka” Salt Mine Health Resort
M. Kostrzon (Wieliczka/PL)14:00 Detection nasal nitric oxide in Slovak healthy adult – reference values and
ID 71 affecting factors
M. Antošová (Martin/SK)

- 14:15
ID 73 Changes in Airway's Defence Mechanisms Control Mediated via Voltage-gated Sodium Channels
M. Kocmalova (Martin/SK)
- 14:30
ID 78 Cough reflex influenced by polysaccharides from the bark of Terminalia Arjuna
V. Sivová (Martin/SK)
- 14:45
ID 102 Content of asthmagen natural rubber latex allergens in commercial disposable gloves
C. Bittner (Hamburg/DE)
- 17:00
ID 101 Multifactoriell Insomnia and the importance of interdisziplinarity in the sleep lab
C. Frohn (Wuppertal/DE)
- 15:30–17:15
Room 1
Chairs **Sleep-related breathing disorders I**
K. Rasche (Wuppertal/DE), O. Oldenburg (Bad Oeynhausen/DE)
- 15:30 The Serve-HF study
O. Oldenburg (Bad Oeynhausen/DE)
- 16:00
ID 13 Usage of mandibular advancement appliance for obstructive sleep apnea treatment
J. Kostrzewa-Janicka (Warsaw/PL)
- 16:15
ID 30 Intermittent hypoxia and unsaturated aldehydes – the effect on oral epithelial wound healing
A. Z. Reznick (Haifa/IL)
- 16:30
ID 54 Increased sclerostin levels in women with obstructive sleep apnea syndrome
M. Kosacka (Wrocław/PL)
- 16:45
ID 59 The blood pressure variability of sleep apnea patients
I. Porębska (Wrocław/PL)
- 15:30–17:15
Room 2
Chairs **Respiratory infections IV**
R. Siekmeier (Bonn/DE), K. Duk (Warsaw/PL)
- 15:30
ID 79 The efficiency of PCR and immunofluorescence methods to detect human cytomegalovirus in the blood and bronchoalveolar lavage fluid
K. Duk (Warsaw/PL)

- 15:45 Diagnosis and treatment of lung mycobacterioses in Slovakia
ID 80 I. Porvazník (Martin/SK)
- 16:00 Concha bullosa in paleoanthropological material
ID 86 A. Gawlikowska-Sroka (Szczecin/PL)
- 16:15 Inhalation of aztreonam for treatment of lung infection in cystic fibrosis
ID 94 and bronchiectasis
R. Siekmeier (Bonn/DE)
- 16:30 Hyponatremia in children hospitalized due to RSV infection¹
ID 99 A. Wrotek (Warsaw/PL)
- 17:45 Benign acute childhood myositis during influenza B outbreak
ID 112 K. Miśkiewicz (Wrocław/PL)
- 15:30–17:15 **Asthma, respiratory allergy and cough IV/Oncology of the chest I**
Room 4-5
Chairs V. Calkovsky (Martin/SK), A. Rzechonek (Wrocław/PL)
- 15:30 IgE reactivity, work related allergic symptoms, asthma severity and quality
ID 103 of life in bakers with occupational asthma
A. M. Preisser (Hamburg/DE)
- 15:45 Lung cancer and multiple neoplasms – a retrospective analysis
ID 12 A. Romaszko (Olsztyn/PL)
- 16:00 The biological and clinical significance of alpha-1 antitrypsin in non-small
ID 14 cell lung cancer
E. Dębek (Warsaw/PL)
- 16:15 Laryngeal cancer – 12-year experience of the single centre
ID 39 V. Calkovsky (Martin/SK)
- 16:30 UGT8 expression in primary non-small cell lung cancer and its lung
ID 41 metastases – preliminary study
A. Rzechonek (Wrocław/PL)
- 16:45 The role of dysregulated microRNA expression in lung cancer¹
ID 50 M. Krutakova (Martin/SK)

¹supported by CMKP grant 501-1-20-19-15

17:00
ID 57

Elderly Lung Cancer Patients with EGFR mutations
I. Porębska (Wrocław/PL)

17:30–19:00
Room 1
Chairs

Oncology/Medical rehabilitation/Sleep related breathing disorders

A. Żebrowska (Katowice/PL), S. Bölükbas (Wuppertal/DE)

17:30

Malignant pleural mesothelioma – Up-to-Date
S. Bölükbas (Wuppertal/DE)

18:00
ID 74

Effects of auditory rehabilitation program and language skills on pulmonary function of deaf adolescents with cochlear implants
A. Żebrowska (Katowice/PL)

18:15
ID 96

The effect of physiotherapy on blood pressure in children with respiratory tract diseases
B. Jerczak (Wrocław/PL)

18:30
ID 110

The analysis of correlation between class E specific antibodies for inhalant allergens and concentrations of metals in a group of pediatric patients
I. Pirogowicz (Wrocław/PL)

18:45
ID 120

Respiratory function tests in children and adolescents during rehabilitation period in Szklarska Poręba, Poland
K. Wrona (Wrocław/PL)

17:30–19:00
Room 2
Chairs

Cardiorespiratory functions

I. Tuleta (Bonn/DE), E. Marek (Bochum/DE)

17:30
ID 113

Streptococcus pneumoniae urinary antigen test as a useful method in the diagnostics and treatment of pneumonia in children
K. Miśkiewicz (Wrocław/PL)

17:45
ID 115

Flu in Poland in 2008–2014¹
A. Wrotek (Warsaw/PL)

18:00
ID 72

Exposure to normobaric hypoxia with exercise training improved glycaemic control and cardiorespiratory fitness in patients with Type 1 Diabetes Mellitus¹
A. Żebrowska (Katowice/PL)

¹supported by CMKP grant 501-1-20-19-15

- 18:15 Sarcoidosis is not associated with increased atherosclerotic plaque burden
ID 104 but with increased pulse wave index
I. Tuleta (Bonn/DE)
- 18:30 Obstructive sleep apnea is related to increased arterial stiffness
ID 105 in ultrasound speckle-tracking analysis
I. Tuleta (Bonn/DE)
- 18:45 Mobile cardio-pulmonary exercise tests in patients over 70 years with
ID 106 coal workers pneumoconiosis
E. Marek (Bochum/DE)
- 17:30–19:00 **Oncology of the chest I**
Room 4-5
Chairs E. Halasova (Martin/SK), J. Rybacka-Mossakowska (Poznan/PL)
- 17:30 Clinical significance of dimeric form of pyruvate kinase as a diagnostic
ID 58 and prognostic biomarker in adenocarcinoma and squamous cell lung cancer
M. Majchrzak (Wrocław/PL)
- 17:45 Intratumoral concurrent punctual freezing and dye injection during surgical
ID 60 resection of primary and secondary lung tumor – a new targeted delivery
technique – preliminary report on 30 patients
A. Rzechonek (Wrocław/PL)
- 18:00 Effect of polymorphisms of selected DNA repair genes on lung cancer
ID 75 development with respect to chromium exposure
E. Halasova (Martin/SK)
- 18:15 Results of pulmonary metastasectomy in lung cancer and colon cancer
ID 77 A. Rzechonek (Wrocław/PL)
- 18:30 Genetic association study of CYP1A2 polymorphisms identifies risk
ID 82 haplotypes in lung cancer in Slovak population
E. Halasova (Martin/SK)
- 18:45 Humoral immune response against neural antigens and its effect on
ID 57 cognition in lung cancer patients
J. Rybacka-Mossakowska (Poznan/PL)

09:15–10:30 **Interstitial lung diseases**

Room 1

Chairs W. Naumnik (Białystok/PL), K. Wrona (Wrocław/PL)

09:15 Polymorphism of FCGR2A, FCGR2B, FCGR2C and FCGR3B genes
ID 16 in the Etiopathogenesis of Sarcoidosis

A. Dubaniewicz (Gdansk/PL)

09:30 The impact of methotrexate on the development of interstitial
ID 51 lung disease in patients with rheumatoid arthritis

J. Kur-Zalewska (Warsaw/PL)

09:45 OPG/sRANKL signalling system in pulmonary sarcoidosis – the
ID 92 bronchoalveolar lavage study

W. Naumnik (Białystok/PL)

10:00 Analysis of health problems of patients in the terminal stage of lung cancer

ID 121 K. Wrona (Wrocław/PL)

10:15 What kind of palliative support do health care professionals need in different
ID 123 hospital? A study about End of Life Care in acute hospital settings using PASKAL
questionnaire

J. Majewski (Wuppertal/DE)

09:15–10:30 **Lung function**

Room 2

Chairs R. Merget (Bochum/DE), E. Kuchar (Warsaw/PL)

09:15 Spirometry or bodyplethysmography for the assessment of bronchia
ID 4 l hyperresponsiveness? – new answers to an old question

R. Merget (Bochum/DE)

09:30 Polish Spirometry Day 2013 and World Spirometry Day 2014 – presentation
ID 21 of selected results

A. Badyda (Warsaw/PL)

09:45 Neurogenic pulmonary edema in aneurismal subarachnoid hemorrhage:
ID 26 an analysis of 250 consecutive patients

A. Saracen (Radom/PL)

10:00 Olfactory sensory neurons (OSNs) presence in the inferior human
ID 28 turbinates – preliminary observations

A. Mazzatenta (Chieti/IT)

10:15 Human volabolome – the physiological effect of
 ID 29 4, 16-androstadien-3-one (AND) administration on exhaled VOCs
 A. Mazzatenta (Chieti/IT)

09:15–10:30 **Oncology of the chest II**

Room 4-5

Chairs S. Michalak (Poznan/PL), E. Halasova (Martin/SK)

09:15 Diagnostic usefulness of [18F]FDG-PET/MRI in patients with Non-Small
 ID 91 Cell Lung Cancer (NSCLC) – pilot study
 R. Mroz (Bialystok/PL)

09:30 Clinical implications of HGF, IL-20 and IL-22 levels in serum and BALF of
 ID 93 advances non-small cell lung cancer (NSCLC)
 W. Naumnik (Bialystok/PL)

09:45 Genotyping of clinically important EGFR mutations from bronchial
 ID 95 cytological specimens in a Slovak Cohort
 E. Halasova (Martin/SK)

10:00 Quality of communication between referring clinicians and radiologists:
 ID 118 How important is it? – an analysis of this problem in imaging of pulmonary
 complications after HSCT in children
 C. Olchowiy (Wrocław/PL)

10:15 The effect of mitochondrial respiratory system in peripheral blood
 ID 119 mononuclear cells on cognition during the course of lung cancer
 S. Michalak (Poznan/PL)

11:00–12:45 **Bronchitis and COPD/Non-invasive ventilation**

Room 1

Chairs K.-J. Franke (Hagen/DE), K. Rasche (Wuppertal/DE)

11:00 Interventional pneumology (emphysem & coil-therapy)
 K.-J. Franke (Hagen/DE)

11:30 Burden of selected respiratory diseases in 11 Polish cities preliminary
 ID 18 screening assessment
 A. Badyda (Warsaw/PL)

- 11:45
ID 46 Evaluation of genetic affinity between yeast-like fungi and *Klebsiella* spp. isolated from the biofilm of removable dental prostheses of patients in stabilized phases of chronic obstructive pulmonary disease
D. Przybyłowska (Warsaw/PL)
- 12:00
ID 84 The analysis of the diet of patients with diagnosed chronic obstructive pulmonary disease as well as its influence on nutrition condition
D. Mękal (Wrocław/PL)
- 12:15
ID 109 Exhaled breath temperature as an indicator of exacerbation in patients with chronic obstructive pulmonary disease
R. Gawlik (Katowice/PL)
- 12:30
ID 69 Product failures in anesthetic apparatuses and their consumables – analysis of field safety notes published by the BfArM 2005–2013
R. Siekmeier (Bonn/DE)
- 11:00–12:45
Room 2
Chairs **Lung function/Pathophysiology of hypoxia**
D. Mokra (Martin/SK), M. Pokorski (Warsaw/PL)
- 11:00
ID 42 Human emotions deciphered by VOCs emission and breath
R. Di Carmine Di Tillio (Chieti/IT)
- 11:15
ID 53 Influence of morphological traits, fat distribution and smoking on respiratory function in adult women
A. John (Poznan/PL)
- 11:30
ID 65 Effects of high-frequency jet ventilation (HFJV) vs. conventional mechanical ventilation (CMV) in two models of acute lung injury
D. Mokra (Martin/SK)
- 11:45
ID 66 Anti-oxidation and anti-inflammatory benefits of combined surfactant and N-acetylcysteine treatment of experimental meconium-induced respiratory failure
D. Mokra (Martin/SK)
- 12:00
ID 67 Effects of nitric oxide donor on inflammation, iNOS activity and apoptosis in an experimental model of acute lung injury
P. Kosutova (Martin/SK)

- 12:15 Shift of regulatory pathways in early and extended stage of myocardial
ID 52 hypertrophy
A. Portnychenko (Kyiv/UA)
- 12:30 The theory of phase metabolic changes at intermittent hypoxic training
ID 87 may be used for the prevention of severe acute immobilization stress
V. Portnichenko (Kyiv/UA)
- 11:00–12:45 **Inflammation and clinical immunology**
Room 4-5
Chairs T. M. Zielonka (Wrocław/PL), J. de Zeeuw (Cologne/DE)
- 11:00 Local irritating effects, exhaled breath condensate pH and exhaled
ID 43 nitric oxide in humans after ethyl acrylate exposure
F. Hoffmeyer (Bochum/DE)
- 11:15 HL-60 cells as a model for studies on the mechanism of neutrophil
ID 68 extracellular traps formation
A. Manda-Handzlik (Warsaw/PL)
- 11:30 Popularity of influenza vaccination among medical personnel of medical
ID 108 facilities in Wrocław
K. Pachotek (Wrocław/PL)
- 11:45 The analysis of immunoglobulin A, M, G blood levels and the correlation
ID 111 with the concentration of light and heavy metals in the blood serum in
adolescents
Ł. Gojny (Wrocław/PL)
- 12:00 Cadmium, zinc, lead, magnesium – Are the serum concentrations of these
ID 116 metals helpful in diagnosing the cause of allergy?
Ł. Gojny (Wrocław/PL)
- 12:15 Immunoglobulins specific for common allergens and their
ID 117 dependence on heavy metal concentrations in the blood
Ł. Gojny (Wrocław/PL)
- 12:30 Infection of *Klebsiella pneumoniae* ESBL among hospitalized patients
ID 122 T. M. Zielonka (Wrocław/PL)



Did You Know?

**Conventus is the professional
Congress Organiser for the**

11th International Conference on
,Advances in Pneumology'.

conventus
CONGRESSMANAGEMENT

A			
Antošová, M.	16	Kocmalova, M.	16, 17
		Kosacka, M.	17
		Kostrzewa-Janicka, J.	17
B			
Badyda, A.	13, 21, 22	Kosutova, P.	23
Bednarska, K.	16	Kotmanova, Z.	15
Bittner, C.	17	Krutakova, M.	18
Buday, T.	13	Kuchar, E.	12, 14, 21
		Kurpas, D.	13, 14
		Kur-Zalewska, J.	21
C			
Calkovsky, V.	18	M	
Carmine Di Tillio, R. Di	23	Majchrzak, M.	20
Chmielewska, M.	14	Manda-Handzlik, A.	24
Cieplak, M.	16	Marek, E.	19, 20
		Mazzatenta, A.	21, 22
D			
Dębek, E.	18	Mękal, D.	23
Duk, K.	12, 17	Merget, R.	21
Dzięciołowska-Baran, E.	12	Mestanik, M.	15
		Michalak, S.	22
		Miśkiewicz, K.	18, 19
F			
Franke, K.-J.	22	Mokra, D.	23
Frohn, C.	17	Mokrý, J.	14
		Mroz, R.	22
G			
Gawlik, R.	23	N	
Gawlikowska-Sroka, A.	18	Naumnik, W.	21, 22
Gojny, Ł.	21, 24	O	
		Olchowy, C.	22
H			
Halasova, E.	20, 22	Oldenburg, O.	17
Hallmann-Szelińska, E.	14	P	
Hoffmeyer, F.	24	Pachofek, K.	24
		Pappová, L.	15
J			
Jama-Kmieciak, A.	16	Pirogowicz, I.	19
Jerczak, B.	19	Pirogowicz-Hirnle, A.	15
John, A.	23	Plevkova, J.	13
		Pokorski, M.	12, 13, 15, 23
		Porębska, I.	17, 19
K			
Kazimierová, I.	15	Portnichenko, V.	24
Kertys, M.	15	Portnychenko, A.	24
Kerzel, S.	12	Porvazník, I.	18
		Preisser, A. M.	18
		Przybyłowska, D.	16, 23
R			
		Reznick, A. Z.	12, 15, 17
		Romaszko, A.	18
		Romaszko, J.	14
		Ruffini, R.	14
		Rybacka-Mossakowska, J.	20
		Rzechonek, A.	18, 20
S			
		Saracen, A.	12, 21
		Siekmeier, R.	12, 16, 17
			18, 23
		Simera, M.	15
		Sivová, V.	17
T			
		Tuleta, I.	19, 20
U			
		Urbanová, A.	16
V			
		Veternik, M.	15
W			
		Werner, F.	13
		Witte, C.	13
		Wrona, K.	19, 21
		Wrotek, A.	18, 19
		Wytrychowski, K.	13
Z			
		Żebrowska, A.	19
		Zeeuw, J. de	12, 24
		Zielonka, T. M.	24
		Zycinska, K.	14

"The moment
I picked it up
I knew what
to do."*

Intuitive by design¹⁻³

- Intuitive to handle¹⁻³
- Ready in one flip of the cover
- For asthma and COPD**



DuoResp[®]
Spiromax[®]
budesonide/formoterol



Please refer to the Summary of Product Characteristics (SmPC) for full details of the Prescribing Information.

DuoResp[®] Spiromax[®] (budesonide/Formoterol) 160 micrograms/4.5 micrograms inhalation powder and **DuoResp[®] Spiromax[®] (budesonide/Formoterol)** 320 micrograms/9 micrograms inhalation powder. **Abbreviated Prescribing Information. Presentation: DuoResp[®] Spiromax[®] 160/4.5:** Each delivered dose contains 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate. This is equivalent to a metered dose of 200 micrograms budesonide and 6 micrograms of formoterol fumarate dihydrate. **DuoResp[®] Spiromax[®] 320/9:** Each delivered dose contains 320 micrograms of budesonide and 9 micrograms of formoterol fumarate dihydrate. This is equivalent to a metered dose of 400 micrograms budesonide and 12 micrograms of formoterol fumarate dihydrate. **Inhalation powder. Indications:** Treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting beta₂-adrenoceptor agonist) is appropriate. COPD: Symptomatic treatment of patients with severe COPD (FEV₁ <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. **Dosage and administration:** Not indicated for use in children, 12 years of age and younger, or adolescents, 13 to 17 years of age.

Asthma: Not intended for the initial management of asthma. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of β₂-adrenoceptor agonists and/or corticosteroids by individual inhalers should be prescribed. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. When control of symptoms is achieved titrate to the lowest effective dose, which could include once daily dosing. **DuoResp[®] Spiromax[®] 160/4.5:** DuoResp[®] Spiromax[®] maintenance therapy – regular maintenance treatment with a separate reliever inhaler. **Adults (18 years and older):** 1-2 inhalations twice daily (maximum of 4 inhalations twice daily). **DuoResp[®] Spiromax[®] maintenance and reliever therapy – regular maintenance treatment and as needed in response to symptoms:** should be considered for patients with: (i) inadequate asthma control and in frequent need of reliever medication; (ii) previous asthma exacerbations requiring medical intervention. **Adults (18 years and older):** The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. For some patients a maintenance dose of 2 inhalations twice daily may be appropriate. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion. A total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. **DuoResp[®]**

Spiromax[®] 320/9: Only to be used as maintenance therapy. **Adults (18 years and older):** 1 inhalation twice daily (maximum of 2 inhalations twice daily). **COPD: Adults (18 years and older):** 1 inhalation twice daily. **Elderly patients (≥65 years old):** No special requirements. **Patients with renal or hepatic impairment:** No data available. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Precautions and warnings:** If treatment is ineffective, or exceeds the highest recommended dose, medical attention must be sought. Patients with sudden and progressive deterioration in control of asthma or COPD should undergo urgent medical assessment. Patients should have their rescue inhaler available at all times. The reliever inhalations should be taken in response to symptoms and are not intended for regular prophylactic use, e.g. before exercise. For such, a separate rapid-acting bronchodilator should be considered. Patients should not be initiated during an exacerbation. Serious asthma-related adverse events and exacerbations may occur. If asthma symptoms remain uncontrolled or worsen, patients should continue treatment and seek medical advice. If paradoxical bronchospasm occurs, treatment should be discontinued immediately. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightforwardly. Systemic effects may occur, particularly at high doses prescribed for long periods, e.g. Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract and glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression. Potential effects on bone density should be considered, particularly in patients on high doses for prolonged periods that have co-existing risk factors for osteoporosis. Prolonged treatment with high doses of inhaled corticosteroids may result in clinically significant adrenal suppression. Additional systemic corticosteroid cover should be considered during periods of stress, e.g. severe infections or elective surgery. Treatment should not be stopped abruptly. Transfer from oral steroid therapy to a budesonide/formoterol fumarate fixed-dose combination may result in the appearance of allergic or arthritic symptoms which will require treatment. In rare cases, tiredness, headache, nausea and vomiting can occur due to insufficient glucocorticosteroid effect and temporary increase in the dose of oral glucocorticosteroids may be necessary. To minimise risk of oropharyngeal candida infection patients should rinse mouth with water. Administer with caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, or severe cardiovascular disorders. The need for, and dose of inhaled corticosteroids should be re-evaluated in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways. Additional blood glucose controls should be considered in diabetic patients. Hypokalaemia may occur at high doses. Particular caution is recommended in unstable or acute severe asthma. Serum potassium levels should be monitored in these patients. As with other

lactose containing products the small amounts of milk proteins present may cause allergic reactions. **Interactions:** Concomitant treatment with potent CYP3A4 inhibitors should be avoided. If this is not possible the time interval between administration should be as long as possible. Not recommended with beta adrenergic blockers (including eye drops) unless compelling reasons. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine), MAOIs and TCAs can prolong the QTc-interval and increase the risk of ventricular arrhythmias. L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance. Concomitant treatment with MAOIs, including agents with similar properties such as turozolidone and procabazine, may precipitate hypertensive reactions. Patients receiving anaesthesia with halogenated hydrocarbons have an elevated risk of arrhythmias. Hypokalaemia may increase the disposition towards arrhythmias in patients taking digitalis glycosides. **Pregnancy and lactation:** Use only when benefits outweigh potential risks. Budesonide is excreted in breast milk; at therapeutic doses no effects on child are anticipated. **Effects on ability to drive and use machines:** No or negligible influence on the ability to drive and use machines.

Adverse reactions: Serious: Immediate and delayed hypersensitivity reactions, e.g. exanthema, urticaria, pruritus, dermatitis, angioedema and anaphylactic reaction, Cushing's syndrome, adrenal suppression, growth retardation, decrease in bone mineral density, hypokalaemia, hyperglycaemia, aggression, psychomotor hyperactivity, anxiety, sleep disorders, depression, behavioural changes, cataract and glaucoma, tachycardia, cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia and extrasystoles, angina pectoris, prolongation of QTc-interval, increases in blood pressure, bronchospasm and paradoxical bronchospasm. **Common:** Candida infections in the oropharynx, headache, tremor, palpitations, mild irritation in the throat, coughing and hoarseness. Consult the Summary of Product Characteristics in relation to other side effects.

Overdose: An overdose of formoterol may lead to: tremor, headache, palpitations. Symptoms reported from isolated cases are tachycardia, hyperglycaemia, hypokalaemia, prolonged QTc-interval, nausea and vomiting. Supportive and symptomatic treatment may be indicated.

Marketing Authorisation Numbers: EU/1/14/920/001 & EU/1/14/920/004. **Marketing Authorisation Holder:** Teva Pharma BV, Computertweg 10, 3542 DR Utrecht, The Netherlands. **Date of Preparation:** March 2014. **Job Code:** HQ/00/15/0019. **References:** 1. Rychlik R, Kreimendahl F. Presented at the 7th PCRG World Conference, 2014. 2. Plusa T, Bijós P. Poster 2805 presented at the European Respiratory Society International Congress, 2014. 3. Plusa T, Bijós P. Poster 2807 presented at the European Respiratory Society International Congress, 2014. 4. DuoResp Spiromax[®] Summary of Product Characteristics.

new!




**HEINEN +
LÖWENSTEIN**
Lebenserhaltende
Medizintechnik



REAL INNOVATION
STARTS IN ONE'S HEAD.

Homecare
Pneumology
Neonatology
Anaesthesia
Intensive care ventilation
Sleep diagnostics
Service
Patient support

LEOSound – Long-term analytics
of palmonary- and breath sounds.
New diagnostics for changed thinking.

Heinen + Löwenstein
Arzbacher Straße 80
D-56130 Bad Ems
Telefon: 0 26 03/96 00-0
Fax: 0 26 03/96 00-40
Internet: hul.de